trial

D-serine Monotherapy for Schizophrenia

NCTId NCT00816894
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 18 (actual)
Sponsored by Herzog Hospital
Primary completion 2013-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
18 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2009-01
Primary completion
2013-02
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
D-serineOlanzapine

Sponsors

Herzog HospitalLead Sponsor
Israel Science FoundationCollaborator

Sites

1 total
Jerusalem, Israel

Linked catalysts

1
D-serine Monotherapy for Schizophrenia — primary completion2013-02

Facts & assertions

4 sourced
Enrollment
18
Phase
PHASE2
Primary Completion Date
2013-02
Status
COMPLETED
relationships
The graph out of here
drug
D-serine
drug
Olanzapine
drug
lead_sponsor
Herzog Hospital
company
collaborator
Israel Science Foundation
company
indication
Schizophrenia
indication
Schizophrenia
indication